☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
PharmaShots Weekly Snapshots (September 30 – October 04, 2024)
October 4, 2024
Teva and mAbxience Join Forces on Second Biosimilar Candidate in Oncology
October 4, 2024
PharmaShots' Key Highlights of Third Quarter 2024
October 1, 2024
Prime Medicine and BMS Join Forces to Develop and Commercialize Various Prime Edited Ex Vivo T-Cell Therapies
October 1, 2024
Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots
September 30, 2024
Genentech Reports the Acquisition of Regor's CDK Inhibitors Portfolio Targeting Breast Cancer
September 30, 2024
PharmaShots Weekly Snapshots (September 23 – September 27, 2024)
September 27, 2024
Zoetis Collaborates with Danone to Develop Sustainable Practices in Dairy Farming Using Genetic Innovation
September 27, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
First Name
Last Name
Daily Newsletter
Weekly Newsletter
I agree to the privacy policy and terms.(
Link
)
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.